Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Parkinson disease in 2017

Changing views after 200 years of Parkinson disease

200 years after James Parkinson's An Essay on the Shaking Palsy, 2017 has seen important advances that are driving a shift towards a broader and more holistic understanding of Parkinson disease aetiology and progression. This shift might finally pave the way to entirely novel and more effective prevention and management strategies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Precision medicine in Parkinson disease.


  1. Obeso, J. A. et al. Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the Shaking Palsy. Mov. Disord. 32, 1264–1310 (2017).

    Article  CAS  Google Scholar 

  2. Espay, A. J. et al. Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Mov. Disord. 32, 319–324 (2017).

    Article  Google Scholar 

  3. Mass, E. et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 549, 389–393 (2017).

    Article  CAS  Google Scholar 

  4. Witoelar, A. et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74, 780–792 (2017).

    Article  Google Scholar 

  5. Pilotto, A. et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Mov. Disord. 32, 1025–1034 (2017).

    Article  CAS  Google Scholar 

  6. Fereshtehnejad, S.-M. et al. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain 140, 1959–1976 (2017).

    Article  Google Scholar 

  7. van Uem, J. et al. Health-related quality of life in patients with Parkinson's disease — a systematic review based on the ICF model. Neurosci. Biobehav. Rev. 61, 26–34 (2016).

    Article  Google Scholar 

  8. Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. Neurol. 15, 249–258 (2016).

    Article  CAS  Google Scholar 

  9. Nieuwhof, F. et al. Impaired dual tasking in Parkinson's disease is associated with reduced focusing of cortico-striatal activity. Brain 140, 1384–1398 (2017).

    Article  Google Scholar 

  10. Mittal, S. et al. β2-adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science 357, 891–898 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Daniela Berg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maetzler, W., Berg, D. Changing views after 200 years of Parkinson disease. Nat Rev Neurol 14, 70–72 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing